Matricelf Ltd. Logo

Matricelf Ltd.

Develops personalized 3D neural implants from patient cells to treat spinal cord injuries.

MTLF | TA

Overview

Corporate Details

ISIN(s):
IL0011767915
LEI:
Country:
Israel
Address:
3 Golda Meir Street, 7651713 Ness Zion
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Matricelf is a preclinical-stage biotechnology company specializing in personalized regenerative medicine. The company develops a proprietary platform for autologous 3D tissue engineering, which creates functional neural implants from a patient's own cells. The technology combines induced Pluripotent Stem Cells (iPSCs) with a personalized hydrogel derived from the patient's extracellular matrix (ECM). This approach is designed to create fully compatible, engineered tissues that promote regeneration without the risk of immune rejection. Matricelf's primary focus is on developing a one-time, curative solution for spinal cord injuries, with its platform also holding potential for treating other conditions such as stroke, traumatic brain injury, and myocardial infarction.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-09-08 20:40
Investor Presentation
COMPANY'S PRESENTATION
Hebrew (modern) 2.3 MB
2024-09-08 20:40
Pre-Annual General Meeting Information
COMPANY'S PRESENTATION
Russian 42.8 KB
2024-03-27 15:30
Investor Presentation
INVESTORS PRESENTATION
English 2.7 MB
2024-03-27 15:30
Pre-Annual General Meeting Information
INVESTORS PRESENTATION
Russian 43.3 KB
2023-02-14 16:31
Investor Presentation
Corporate Presentation - February2023
English 1.1 MB
2023-02-14 16:31
Regulatory News Service
Corporate Presentation - February2023
Russian 42.7 KB
2022-03-16 10:59
Investor Presentation
INVESTORS PRESENTATION
English 2.7 MB
2022-03-16 10:59
Pre-Annual General Meeting Information
INVESTORS PRESENTATION
Russian 41.6 KB
2021-06-17 18:14
Regulatory News Service
Opening of Trading On Sunday June 20, 2021, Appointment of a Market Maker
Hebrew (modern) 256.5 KB
2021-06-14 14:20
Regulatory News Service
Identifying Details of New Security: MATRICELF, MATRICELF.W1
Hebrew (modern) 177.2 KB

Automate Your Workflow. Get a real-time feed of all Matricelf Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Matricelf Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.